Beneficial Effects of the Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia in Patients With Postpsychotic Depressive Disorder of Schizophrenia: Report of 5 Cases

LOGIN

REGISTER


Forgot your login? GET HELP

Objective: Tardive dyskinesia (TD) is characterized by involuntary, repetitive, purposeless movements that can affect different parts of the body. Tardive dyskinesia is a well-known side effect of conventional antipsychotics and commonly occurs after several years of treatment. The effective treatment of TD is unclear. Recently, the sigma-1 receptor agonist fluvoxamine was reported to be beneficial for hyperkinetic movement disorders.

Method: We report 5 cases with postpsychotic depressive disorder of schizophrenia and TD. All patients were given fluvoxamine 100 mg/d, and after the second week the dosage of fluvoxamine was increased to 200 mg/d. At the fourth week, patients were assessed in terms of TD and postpsychotic depressive disorder of schizophrenia.

Results: Fluvoxamine was found to be beneficial for TD and postpsychotic depressive disorder of schizophrenia in all patients by the fourth week.

Conclusions: Recently, the sigma-1 receptor agonist fluvoxamine has been considered beneficial for various neuropsychiatric disorders. However, data about the effects of fluvoxamine on hyperkinetic movement disorders are limited. In this report, we attempted to demonstrate the beneficial effects of fluvoxamine on TD, and we suggest that the mechanism of action might be due to sigma-1 agonism. Further detailed, double-blind studies should clarify the potential use of fluvoxamine in the treatment of hyperkinetic movement disorders.

Prim Care Companion CNS Disord 2012;14(6):doi:10.4088/PCC.12br01401

Submitted: April 24, 2012; accepted May 29, 2012.

Published online: November 8, 2012.

Corresponding author: Yakup Albayrak, MD, Kırklareli Devlet Hastanesi, Psikiyatri Klinigi, Kırklareli, Turkey (dr.fuge@hotmail.com).

Prim Care Companion CNS Disord 2012;14(6):doi:10.4088/PCC.12br01401

https://doi.org/10.4088/PCC.12br01401